Annual Report · 10-K
Gilead Sciences, Inc.
GILDNASDAQEQUITYCurrent
Annual Report
Company context
Gilead and Kite Oncology are working to transform how cancer is treated. We are innovating with next-generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. We are purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody-drug conjugate technologies and small molecules to cell therapy-based approaches, we are creating new possibilities for people with cancer.
Current securities
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗